 Immunoglobulin Fc Fragments
"Immunoglobulin Fc Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007141
|
| MeSH Number(s) |
D12.644.541.500.697 D12.776.124.486.485.538.500 D12.776.124.486.485.680.697 D12.776.124.790.651.538.500 D12.776.124.790.651.680.660 D12.776.377.715.548.538.500 D12.776.377.715.548.680.660
|
| Concept/Terms |
Immunoglobulin Fc Fragments- Immunoglobulin Fc Fragments
- Fc Fragments, Immunoglobulin
- Immunoglobulins, Fc Fragment
- Fc Fragment Immunoglobulins
- Fragment Immunoglobulins, Fc
- Immunoglobulin Fc Fragment
- Fc Fragment, Immunoglobulin
- Immunoglobulins, Fc
- Fc Fragments
- Fc Immunoglobulins
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fc Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fc Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fc Fragments" by people in this website by year, and whether "Immunoglobulin Fc Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 1 | 2 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 5 | 0 | 5 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 3 | 4 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoglobulin Fc Fragments" by people in Profiles.
-
Muthuraman K, Jackman M, Liang Y, Garrett ME, Cui H, Nguyen LVH, Ivanochko D, Ye C, Pino PA, Hicks A, Maingot B, Yusko E, Benzeno S, Martínez-Sobrido L, Torrelles JB, Gilbert AE, Rubin BER, Keitany G, Jetha A, Julien J-P. Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions. J Virol. 2025 12 23; 99(12):e0152325.
-
Derington CG, Sarwal A, Wei G, Hartsell SE, Throolin M, Singh R, Nevers MR, Zhang C, Katkam N, Takyi A, Chakravartula AR, Babu P, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Shen J, Beddhu S. Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Netw Open. 2025 Oct 01; 8(10):e2537297.
-
McMahon C, Raddi MG, Mohan S, Santini V. New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473654.
-
Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024 Sep 01; 47(9):1617-1621.
-
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022 08 04; 387(5):433-443.
-
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 12; 22(12):1740-1751.
-
Gorman MJ, Patel N, Guebre-Xabier M, Zhu AL, Atyeo C, Pullen KM, Loos C, Goez-Gazi Y, Carrion R, Tian JH, Yuan D, Bowman KA, Zhou B, Maciejewski S, McGrath ME, Logue J, Frieman MB, Montefiori D, Mann C, Schendel S, Amanat F, Krammer F, Saphire EO, Lauffenburger DA, Greene AM, Portnoff AD, Massare MJ, Ellingsworth L, Glenn G, Smith G, Alter G. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep Med. 2021 09 21; 2(9):100405.
-
Takeda K, Kim SH, Joetham A, Petrache I, Gelfand EW. Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema. Respir Res. 2021 Jul 16; 22(1):207.
-
Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, Liu STH, Simon V, Krammer F, Ward AB, Palese P, Wilson PC, Nachbagauer R. Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Balcioglu O, Heinz RE, Freeman DW, Gates BL, Hagos BM, Booker E, Mirzaei Mehrabad E, Diesen HT, Bhakta K, Ranganathan S, Kachi M, Leblanc M, Gray PC, Spike BT. CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress. Breast Cancer Res. 2020 11 13; 22(1):125.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|